Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate

NATICK, Mass., Oct. 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy Klobuchar (D-MN) and cosponsored by Sens. Richard Burr (R-NC) and Michael Bennet (D-CO).  The legislation is intended to streamline the medical device review and approval process, reduce regulatory delays and help new medical technologies safely and more expeditiously reach patients.

Boston Scientific commends Senators Klobuchar, Burr and Bennet for their thoughtful leadership in introducing this new legislation designed to streamline the Food and Drug Administration's regulation of medical devices.  This bill is an important step in transforming the process of bringing life-enhancing and life-saving medical technologies to market in a safe and more efficient and predictable manner. 

Boston Scientific looks forward to collaborating with the sponsoring senators and other Members of Congress on this important piece of legislation.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

CONTACT:

Erik Kopp


508-650-8660 (office)


Media Relations


Boston Scientific Corporation


[email protected]




Sean Wirtjes


508-652-5305 (office)


Investor Relations


Boston Scientific Corporation


[email protected]



SOURCE Boston Scientific Corporation

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.